Morningside Ventures, IAG Capital Partners and Starbloom Capital led $105m Series C round in Cognito Therapeutics.

Morningside Ventures, IAG Capital Partners and Starbloom Capital, a private equity firms, led $105m Series C round in Cognito Therapeutics, late clinical-stage neurotechnology company, with participation from New Vintage, Apollo Health Ventures and Benvolio Group. “With this financing, we are entering a pivotal moment for our company, and for the patients and families waiting for new options in Alzheimer’s disease. Spectris has the potential to become the world’s first physician-prescribed, at-home neuroprotective therapy for patients diagnosed with Alzheimer’s, designed to preserve cognition and daily function. This funding allows us to make this therapy accessible to those who need it most,” Christian Howell, Cognito Therapeutics CEO.